Using Open-Source Software to Drive Reliability and Security in Lab & Life Sciences

 

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to bringing new advancements to life. 

Health and Life Science at the Edge’s Morgan Andersen welcomed Intel Product Manager Amy Gilliam and Director of Security Communications Christopher Robinson for a discussion on open-source, everything from what it is, what the culture is like, and managing the quality of the code.

Gilliam says the culture around open source has grown to become a collaborative environment that’s enhanced over the years. Open exchange, de-centralized coding collaboration and peer review are all norms that move open source in a positive direction. “Peer review is a huge part of the open-source development process, in which developers submit code, it gets reviewed by multiple team members and project members before it gets integrated into the main code base by the maintainer,” Gilliam adds. 

From Robinson’s perspective, open source thrives because of the collaboration community. “I’ve been doing security in upstream open source for just under a decade, and I get to work with people from all around the world. We used to have a concept frequently talked about; it was called meritocracy; whereas you were contributing to these communities, people would put forth other ideas, and normally the best idea will win out. After much review and conversation, you’ll generally have better quality code because you’ve had all these different types of inputs.” 

So, how does security factor into open source when privacy is critical to a lot of work done in the health and life science world? Some essential regulations and rules govern the industry to protect human life. Gilliam says technology developers must familiarize themselves with these regulations and ensure the flexibility and capability to meet those compliance requirements now and in the future. 

“The FDA requires disclosures of software submission,” Gilliam said. “So, along with those disclosures of software, are usually calling out of risks and mitigations. Those can be cybersecurity risks, privacy risks, etc. We’re monitoring for that as we’re building software and these analytical tools that will help leverage and accelerate processes in the pharmaceutical industry.” 

Learn more about Open Source solutions by connecting with Amy Gilliam and Christopher Robinson on LinkedIn or visit Intel Health and Life Sciences. 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

promoted
How to Succeed After Getting Promoted: Seeking Feedback, Acting with Intention, and Leading with Perspective
April 16, 2026

Stepping into a leadership role today isn’t just a step up—it’s a shift into constant visibility, where expectations arrive immediately and the margin for error narrows. As organizations flatten structures and demand faster decisions, newly promoted leaders are expected to deliver impact from the outset, often without the space to fully adjust. According to…

Read More
AI in business
A Practical Conversation About AI in Business: From Hype to Real-World Impact
April 15, 2026

Artificial intelligence has moved from buzzword to boardroom priority at a staggering pace. Yet despite widespread adoption, many organizations are still struggling to turn experimentation into measurable business value—some estimates suggest the majority of enterprise AI initiatives fail to scale successfully. As AI becomes “table stakes” across industries, the real challenge is no longer…

Read More
weekly drive-in
Metropolis: Weekly Drive-in
April 15, 2026

Metropolis “Weekly Drive In” reflects a new era of storytelling where AI meets real-world execution, turning everyday field performance into momentum. Centered on genuine conversions and local wins, the series highlights how the company is scaling not just through technology, but through visibility and shared recognition. In an emerging recognition economy, these updates act…

Read More
Drive In, Drive Out: The Rhythm of Metropolis
April 15, 2026

Behind the seemingly mundane choreography of a drive-in lies a broader story about how modern cities script behavior, turning even the simplest actions into rehearsed routines. What looks like repetition is really a quiet testament to systems designed for flow and control, where efficiency often outweighs individuality. In places like Metropolis, the rhythm of…

Read More